Go Pro

Nukkleus (NUKKW) 10K Form and Latest SEC Filings 2026

$0.07 +0.00 (+7.10%)
As of 06/30/2026

Latest Nukkleus SEC Filings & Recent Activity

Nukkleus (NASDAQ:NUKKW) has submitted 225+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 424B3 submitted on July 1, 2026.

Form 4
T3 Defense Inc. Reports Ownership Change on Apr. 28, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Nukkleus Files Current Report on Jun. 29, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Nukkleus Files Quarterly Report on May. 20, 2026

The 10-Q contains Nukkleus's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Nukkleus SEC Filing History

Browse Nukkleus' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
07/01/2026 9:20 AM
Nukkleus (1787518) Filer
Form 424B3
06/30/2026 11:15 PM
Nukkleus (1787518) Filer
Form EFFECT
06/29/2026 4:25 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2026 4:11 PM
Nukkleus (1787518) Filer
Form S-1/A
06/18/2026 4:25 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/15/2026 4:25 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2026 11:55 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2026 11:55 AM
Cohen Roy (2137926) Reporting
Nukkleus (1787518) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/04/2026 4:30 PM
Nukkleus (1787518) Filer
Form S-1
Registration statement under Securities Act of 1933  
05/27/2026 5:07 AM
Nukkleus (1787518) Filer
Form DEF 14A
05/21/2026 7:01 AM
Nukkleus (1787518) Subject
VisionWave Holdings, Inc. (2038439) Filed by
Form SCHEDULE 13G
05/20/2026 4:01 PM
Nukkleus (1787518) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/15/2026 4:25 PM
Nukkleus (1787518) Filer
Form NT 10-Q
04/28/2026 7:30 AM
Shalom Menachem (2030245) Reporting
Nukkleus (1787518) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 7:15 AM
Shalom Menachem (2030245) Filed by
Nukkleus (1787518) Subject
Form SCHEDULE 13D/A
04/28/2026 7:05 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/16/2026 3:20 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/15/2026 3:20 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/14/2026 3:05 PM
Nukkleus (1787518) Filer
Form PRE 14A
04/14/2026 7:00 AM
BiomX Inc. (1739174) Subject
Nukkleus (1787518) Filed by
Form SCHEDULE 13D/A
04/10/2026 2:40 PM
BiomX Inc. (1739174) Subject
Nukkleus (1787518) Filed by
Form SCHEDULE 13D
04/10/2026 11:50 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/09/2026 1:29 PM
Nukkleus (1787518) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
04/07/2026 7:30 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/03/2026 8:09 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/01/2026 7:50 AM
Nukkleus (1787518) Filer
Form 8-K/A
03/31/2026 3:46 PM
Nukkleus (1787518) Filer
Form NT 10-K
03/12/2026 10:31 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2026 4:28 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/02/2026 8:12 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/25/2026 10:18 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/20/2026 4:25 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 8:20 PM
Esousa Group Holdings LLC (2033034) Filed by
Nukkleus (1787518) Subject
Form SCHEDULE 13G/A
02/17/2026 7:30 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/16/2026 11:15 PM
Nukkleus (1787518) Filer
Form EFFECT
02/13/2026 4:21 PM
Nukkleus (1787518) Filer
Form 424B3
02/13/2026 5:45 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/11/2026 3:18 PM
Nukkleus (1787518) Filer
Form S-1
Registration statement under Securities Act of 1933  
02/09/2026 7:52 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/03/2026 7:45 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/22/2026 4:01 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Urgent exposé on the "Mar-a-Lago Trade" (Ad)

Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent exposé on what he calls the $7.2 trillion 'Mar-a-Lago Trade.' Bloomberg warns it may cause 'a dire shift of fortunes for America.' Eifrig, who called the 2022 crash months early, says this event is already underway and could move as high as 10x from current levels. Over 500,000 paid subscribers follow his research. Access the full free broadcast before it comes down.tc pixel

Watch Dr. Eifrig's free broadcast and get the full story now
01/20/2026 6:57 PM
Nukkleus (1787518) Issuer
Shalom Menachem (2030245) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 6:38 PM
Nukkleus (1787518) Subject
Shalom Menachem (2030245) Filed by
Form SCHEDULE 13D
01/16/2026 7:30 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/14/2026 3:05 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2026 7:30 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/31/2025 4:00 PM
Kotaieva Anastasiia (2045096) Reporting
Nukkleus (1787518) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2025 9:10 AM
Kotaieva Anastasiia (2045096) Reporting
Nukkleus (1787518) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 10:08 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/23/2025 3:50 PM
Nukkleus (1787518) Filer
Form 424B3
12/23/2025 3:50 PM
Nukkleus (1787518) Filer
Form 424B3
12/22/2025 3:15 PM
Kotaieva Anastasiia (2045096) Reporting
Nukkleus (1787518) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 4:19 PM
Nukkleus (1787518) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/17/2025 4:19 PM
Nukkleus (1787518) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/17/2025 4:27 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/17/2025 3:01 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/11/2025 8:23 AM
Nukkleus (1787518) Filer
Form DEFA14A
12/09/2025 3:30 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/01/2025 4:20 PM
Nukkleus Defense Technologies, Inc. (2095058) Reporting
Nukkleus (1787518) Reporting
SC Capital II Sponsor LLC (2076738) Reporting
SC II Acquisition Corp. (2076739) Issuer
SC II Acquisition Corp. (2076739) Issuer
Shalom Menachem (2030245) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/28/2025 12:05 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2025 8:00 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2025 7:37 PM
Nukkleus Defense Technologies, Inc. (2095058) Reporting
Nukkleus (1787518) Reporting
SC Capital II Sponsor LLC (2076738) Reporting
SC II Acquisition Corp. (2076739) Issuer
SC II Acquisition Corp. (2076739) Issuer
Shalom Menachem (2030245) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/25/2025 4:25 PM
Nukkleus (1787518) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
11/25/2025 4:28 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2025 8:28 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2025 8:06 AM
Nukkleus (1787518) Filer
Form DEF 14A
11/20/2025 1:26 PM
Nukkleus (1787518) Issuer
Volodarsky Aviya (2045038) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 1:27 PM
Nukkleus (1787518) Issuer
Rokach David (2044737) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 1:27 PM
Nukkleus (1787518) Issuer
Yeganeh Reuven (2044677) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 1:27 PM
Nagar Tomer (2050376) Reporting
Nukkleus (1787518) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/17/2025 4:29 PM
Nukkleus (1787518) Issuer
Shalom Menachem (2030245) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 4:05 PM
Nukkleus (1787518) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/14/2025 3:05 PM
Esousa Group Holdings LLC (2033034) Filed by
Nukkleus (1787518) Subject
Form SCHEDULE 13G/A
11/10/2025 4:29 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/28/2025 4:29 PM
Nukkleus (1787518) Filer
Form PRER14A
10/24/2025 3:15 PM
Kotaieva Anastasiia (2045096) Reporting
Nukkleus (1787518) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2025 8:21 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/16/2025 3:50 PM
Nukkleus (1787518) Filer
Form DEF 14A
10/10/2025 6:05 PM
Kotaieva Anastasiia (2045096) Reporting
Nukkleus (1787518) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 8:29 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/19/2025 8:30 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/18/2025 4:27 PM
Nukkleus (1787518) Filer
Form D
Notice of Exempt Offering of Securities 
09/16/2025 8:29 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/15/2025 3:23 PM
Nukkleus (1787518) Filer
Form RW
09/02/2025 4:27 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/02/2025 7:39 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/29/2025 7:13 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/25/2025 3:05 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 4:05 PM
Nukkleus (1787518) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/08/2025 7:00 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2025 8:12 AM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Do NOT Buy SpaceX – Do This Instead (Ad)

SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel

Read Tilson's free analysis and find out what to do with your money
07/29/2025 4:17 PM
Nukkleus (1787518) Filer
Form PRER14A
07/29/2025 4:27 PM
Nukkleus (1787518) Filer
Form S-1/A
07/25/2025 3:01 PM
Nukkleus (1787518) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/15/2025 7:34 AM
Esousa Group Holdings LLC (2033034) Filed by
Nukkleus (1787518) Subject
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Nukkleus SEC Filings - Frequently Asked Questions

Nukkleus (NUKKW) has submitted 225+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 424B3 submitted on July 1, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:NUKKW) was last updated on 7/2/2026 by MarketBeat.com Staff.
From Our Partners